← Leaderboards
George M Shaw
University Of Pennsylvania
$56,045,759
Attributed
$62,183,432
Total exposure
27
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.4M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$107,547,857 · 29
By mechanism
P01$62,205,517 · 12
R01$24,021,004 · 7
U19$6,547,244 · 3
R61$4,748,429 · 1
R33$4,656,240 · 2
R37$2,333,353 · 1
Top collaborators
- Raiees Ahmad Andrabi11 shared
- Alexander Ploss2 shared
- Charles M. Rice2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Mirko Paiardini$32,628,549
- Katharine June Bar$15,418,177
- Michael R Betts$25,350,826
- Irwin M Chaiken$15,499,914
- Dennis Larry Kolson$16,900,832
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1Macaca MulattaAntibodiesMolecularInfectionVaccine DesignVirusVaccinesSimian Human Immunodeficiency VirusBaseLaboratoriesDesignNeutralizing AntibodyEpitopesResponseVaccine ResearchAntigensB-LymphocytesPathway InteractionsTransmission ProcessLeadAnimalsHiv-1 VaccinePolysaccharides
Grant awards (109)
SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design$3,930,527
P01 · FY2025 · AI · contact PI
Project 2: Development of vaccines in preclinical models to induce V2-apex bnAb responses$2,750,363
U19 · FY2025 · AI · contact PI
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies$1,606,895
R33 · FY2025 · AI
Env-Ab coevolution in SHIV infected RMs leading to V3 glycan bNAbs$1,455,232
P01 · FY2025 · AI · contact PI
B cell lineage directed rational vaccine strategies based on CAP256SU Env-Ab coevolution$960,412
R01 · FY2025 · AI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies$804,299
R01 · FY2025 · AI · contact PI
SHIV-guided design of novel HIV-1 fusion peptide immunogens$783,400
R01 · FY2025 · AI · contact PI
Administration$117,333
P01 · FY2025 · AI · contact PI
SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design$4,076,804
P01 · FY2024 · AI · contact PI
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies$1,638,145
R33 · FY2024 · AI
Env-Ab coevolution in SHIV infected RMs leading to V3 glycan bNAbs$1,482,311
P01 · FY2024 · AI · contact PI
B cell lineage directed rational vaccine strategies based on CAP256SU Env-Ab coevolution$960,412
R01 · FY2024 · AI
SHIV-guided design of novel HIV-1 fusion peptide immunogens$807,628
R01 · FY2024 · AI · contact PI
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design$804,299
R01 · FY2024 · AI · contact PI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies$804,299
R01 · FY2024 · AI · contact PI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies$795,113
R01 · FY2024 · AI · contact PI
Administration$121,703
P01 · FY2024 · AI · contact PI
SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design$4,104,830
P01 · FY2023 · AI · contact PI
Env-Ab coevolution in SHIV infected RMs leading to V3 glycan bNAbs$1,405,624
P01 · FY2023 · AI · contact PI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies$1,161,799
R01 · FY2023 · AI · contact PI
Combining germline-targeting, B cell immunofocusing and Env-Ab co-evolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies$1,134,239
R61 · FY2023 · AI
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design$804,299
R01 · FY2023 · AI · contact PI
B cell lineage directed rational vaccine strategies based on CAP256SU Env-Ab coevolution$743,559
R01 · FY2023 · AI
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies$490,507
R61 · FY2023 · AI
B cell lineage directed rational vaccine strategies based on CAP256SU Env-Ab coevolution$133,449
R01 · FY2023 · AI
Administration$121,703
P01 · FY2023 · AI · contact PI
SHIV Env-antibody coevolution as a molecular guide to HIV-1 V3 glycan targeted vaccine design$4,178,808
P01 · FY2022 · AI · contact PI
Combining germline-targeting, B cell immunofocusing and Env-Ab co-evolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies$1,618,119
R61 · FY2022 · AI
Env-Ab coevolution in SHIV infected RMs leading to V3 glycan bNAbs$1,405,625
P01 · FY2022 · AI · contact PI
B cell lineage directed rational vaccine strategies based on CAP256SU Env-Ab coevolution$881,590
R01 · FY2022 · AI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies$804,299
R01 · FY2022 · AI · contact PI
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design$804,299
R01 · FY2022 · AI · contact PI
Administration$121,701
P01 · FY2022 · AI · contact PI
SHIV/HIV Env-Antibody Coevolution as a Guide to Iterative Vaccine Design$3,218,740
P01 · FY2021 · AI · contact PI
Combining germline-targeting, B cell immunofocusing and Env-Ab co-evolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies$1,505,564
R61 · FY2021 · AI
Env evolution in humans and RMs$1,093,737
P01 · FY2021 · AI · contact PI
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design$803,474
R01 · FY2021 · AI · contact PI
HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies$803,267
R01 · FY2021 · AI · contact PI
Administrative Core$125,438
P01 · FY2021 · AI · contact PI
SHIV/HIV Env-Antibody Coevolution as a Guide to Iterative Vaccine Design$3,242,287
P01 · FY2020 · AI · contact PI
Env evolution in humans and RMs$1,097,115
P01 · FY2020 · AI · contact PI
bNAb induction by antigenically diverse V1V2 lineage specific SHIVs and SOSIPs$796,855
R01 · FY2020 · AI · contact PI
Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccines$703,267
R01 · FY2020 · AI · contact PI
Project 3: To define the genetic identity of infecting, superinfecting, and reinfecting strains of HCV and the dynamics of virus elimination, replacement or persistence$156,213
U19 · FY2020 · AI · contact PI
Administrative Core$143,127
P01 · FY2020 · AI · contact PI
SHIV/HIV Env-Antibody Coevolution as a Guide to Iterative Vaccine Design$3,256,887
P01 · FY2019 · AI · contact PI
Env evolution in humans and RMs$1,234,052
P01 · FY2019 · AI · contact PI
bNAb induction by antigenically diverse V1V2 lineage specific SHIVs and SOSIPs$796,855
R01 · FY2019 · AI · contact PI
Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccines$706,916
R01 · FY2019 · AI · contact PI
Project 3: To define the genetic identity of infecting, superinfecting, and reinfecting strains of HCV and the dynamics of virus elimination, replacement or persistence$216,667
U19 · FY2019 · AI · contact PI
Administrative Core$138,129
P01 · FY2019 · AI · contact PI
SHIV/HIV Env-Antibody Coevolution as a Guide to Iterative Vaccine Design$3,269,168
P01 · FY2018 · AI · contact PI
Env evolution in humans and RMs$1,238,707
P01 · FY2018 · AI · contact PI
bNAb induction by antigenically diverse V1V2 lineage specific SHIVs and SOSIPs$796,855
R01 · FY2018 · AI · contact PI
Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccines$712,679
R01 · FY2018 · AI · contact PI
Project 3: To define the genetic identity of infecting, superinfecting, and reinfecting strains of HCV and the dynamics of virus elimination, replacement or persistence$157,619
U19 · FY2018 · AI · contact PI
Administrative Core$154,423
P01 · FY2018 · AI · contact PI
SHIV/HIV Env-Antibody Coevolution as a Guide to Iterative Vaccine Design$3,342,300
P01 · FY2017 · AI · contact PI
Env evolution in humans and RMs$1,228,300
P01 · FY2017 · AI · contact PI
bNAb induction by antigenically diverse V1V2 lineage specific SHIVs and SOSIPs$796,855
R01 · FY2017 · AI · contact PI
Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccines$716,155
R01 · FY2017 · AI · contact PI
Project 3: To define the genetic identity of infecting, superinfecting, and reinfecting strains of HCV and the dynamics of virus elimination, replacement or persistence$152,632
U19 · FY2017 · AI · contact PI
Administrative Core$136,850
P01 · FY2017 · AI · contact PI
Targeting 5' leader-encoded defective ribosomal products for HIV T cell vaccines$749,101
R01 · FY2016 · AI · contact PI
Project 3: To define the genetic identity of infecting, superinfecting, and reinfecting strains of HCV and the dynamics of virus elimination, replacement or persistence$234,059
U19 · FY2016 · AI · contact PI
Penile transmission and neutralization of pathogenic SIVsmm$735,960
R01 · FY2015 · AI · contact PI
Virology$491,469
U19 · FY2015 · AI · contact PI
Cloning, characterization and in vivo testing of mucosally transmitted SIV$480,000
R33 · FY2015 · AI · contact PI
Novel SIVsmm strains for analysis of mucosal transmission and vaccine protection$2,514,879
P01 · FY2014 · AI · contact PI
Virology$1,005,592
U19 · FY2014 · AI · contact PI
Molecular analysis of the mucosal SIVsmm transmission bottleneck$870,987
P01 · FY2014 · AI · contact PI
Penile transmission and neutralization of pathogenic SIVsmm$735,960
R01 · FY2014 · AI · contact PI
Cloning, characterization and in vivo testing of mucosally transmitted SIV$480,000
R33 · FY2014 · AI · contact PI
Transmitted/Founder HCV clones as targets for treatment and eradication.$204,546
R21 · FY2014 · AI · contact PI
Administration$150,845
P01 · FY2014 · AI · contact PI
Novel SIVsmm strains for analysis of mucosal transmission and vaccine protection$2,826,440
P01 · FY2013 · AI · contact PI
Penile transmission and neutralization of pathogenic SIVsmm$691,804
R01 · FY2013 · AI · contact PI
Molecular analysis of the mucosal SIVsmm transmission bottleneck$657,126
P01 · FY2013 · AI · contact PI
Virology$474,799
U19 · FY2013 · AI · contact PI
Cloning, characterization and in vivo testing of mucosally transmitted SIV$451,200
R33 · FY2013 · AI · contact PI
Transmitted/Founder HCV clones as targets for treatment and eradication.$247,296
R21 · FY2013 · AI · contact PI
Administration$117,949
P01 · FY2013 · AI · contact PI
Novel SIVsmm strains for analysis of mucosal transmission and vaccine protection$2,591,606
P01 · FY2012 · AI · contact PI
Penile transmission and neutralization of pathogenic SIVsmm$735,960
R01 · FY2012 · AI · contact PI
Molecular analysis of the mucosal SIVsmm transmission bottleneck$683,133
P01 · FY2012 · AI · contact PI
Virology$533,586
U19 · FY2012 · AI · contact PI
Administration$115,109
P01 · FY2012 · AI · contact PI
Novel SIVsmm strains for analysis of mucosal transmission and vaccine protection$2,554,863
P01 · FY2011 · AI · contact PI
Molecular analysis of the mucosal SIVsmm transmission bottleneck$636,153
P01 · FY2011 · AI · contact PI
Penile transmission and neutralization of pathogenic SIVsmm$590,906
R01 · FY2011 · AI · contact PI
Virology$374,245
U19 · FY2011 · AI · contact PI
Administration$165,903
P01 · FY2011 · AI · contact PI
Cloning, characterization and in vivo testing of mucosally transmitted SIV$107,359
R21 · FY2011 · AI · contact PI
Cloning, characterization and in vivo testing of mucosally transmitted SIV$104,896
R21 · FY2011 · AI · contact PI
Penile transmission and neutralization of pathogenic SIVsmm$94,979
R01 · FY2011 · AI · contact PI
Novel SIVsmm strains for analysis of mucosal transmission and vaccine protection$2,256,286
P01 · FY2010 · AI · contact PI
Molecular analysis of the mucosal SIVsmm transmission bottleneck$470,339
P01 · FY2010 · AI · contact PI
Cloning, characterization and in vivo testing of mucosally transmitted SIV$200,802
R21 · FY2010 · AI · contact PI
Administration$152,438
P01 · FY2010 · AI · contact PI
Biophysical/Genetic Properties of HIV1 in Human Plasma$309,344
R37 · FY2007 · AI · contact PI
Biophysical/Genetic Properties of HIV1 in Human Plasma$318,584
R37 · FY2006 · AI · contact PI
Biophysical/Genetic Properties of HIV1 in Human Plasma$326,250
R37 · FY2005 · AI
Biophysical/Genetic Properties of HIV1 in Human Plasma$326,250
R37 · FY2004 · AI
Biophysical/Genetic Properties of HIV1 in Human Plasma$326,250
R37 · FY2003 · AI
BIOPHYSICAL/GENETIC PROPERTIES OF HIV1 IN HUMAN PLASMA$249,419
R37 · FY2002 · AI
HIV ACUTE INFECTION &EARLY DISEASE UNIT$1,099,523
U01 · FY2001 · AI
BIOPHYSICAL/GENETIC PROPERTIES OF HIV1 IN HUMAN PLASMA$242,154
R37 · FY2001 · AI
HIV ACUTE INFECTION &EARLY DISEASE UNIT$1,071,648
U01 · FY2000 · AI
BIOPHYSICAL/GENETIC PROPERTIES OF HIV1 IN HUMAN PLASMA$235,102
R37 · FY2000 · AI